The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase.
Direct cell counting and extent of [3H]thymidine incorporation demonstrated valproate to inhibit C6 glioma proliferation rate in a dose-dependent manner with a 1 mM concentration achieving 50% inhibition. The antiproliferative effect was reversible and could not be attributed to cytotoxicity at the valproate concentrations employed. The site of valproate action within the cell cycle was determined to be in the G1 phase, at a point 6-6.5 h prior to S phase, by estimating the time to increased [3H]thymidine incorporation following release from a 70% proliferative arrest. Synchronised cells obtained by a mitotic selection procedure required 11-12 h to enter S phase and demonstrated the valproate restriction point to be 5 h into the G1 phase of the C6 cell cycle. Exposure of valproate to the part of the G1 period which follows the restriction point was without effect on cell entry into S phase.
Department of Pharmacology, University College, Belfield, Dublin, Ireland.
M L
ML
Martin
C M
CM
Regan
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D016193:G1 Phase / Q000187:drug effects; D005910:Glioma; D007700:Kinetics; D009457:Neuroglia / Q000166:cytology / Q000187:drug effects; D013723:Teratogens / Q000494:pharmacology*; D013936:Thymidine / Q000378:metabolism; D014635:Valproic Acid / Q000494:pharmacology*
D013723:Teratogens; D014635:Valproic Acid; D013936:Thymidine